BAIYUNSHAN PH's Subsidiary Receives Approval for Supplemental Applications of Cefuroxime Sodium and Candesartan Cilexetil Tablets

Stock News

05/11

BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the "Drug Supplemental Application Approval Notice" from the National Medical Products Administration for Cefuroxime Sodium for Injection 0.5g (calculated as C16H16N4O8S) and Candesartan Cilexetil Tablets 4mg. The approval indicates that the impurity pharmaceutical research for these drugs has been recognized, which is expected to enhance the quality control capabilities and market competitiveness of these products. This approval is not expected to have a significant impact on the company's current financial performance.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1152675607"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152675607\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152675607?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152675607","market":"fut","top_or_hot":-1,"title":"BAIYUNSHAN PH's Subsidiary Receives Approval for Supplemental Applications of Cefuroxime Sodium and Candesartan Cilexetil Tablets","media":"Stock News","content":"<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the \"Drug Supplemental Application Approval Notice\" from the National Medical Products Administration for Cefuroxime Sodium for Injection 0.5g (calculated as C16H16N4O8S) and Candesartan Cilexetil Tablets 4mg. The approval indicates that the impurity pharmaceutical research for these drugs has been recognized, which is expected to enhance the quality control capabilities and market competitiveness of these products. This approval is not expected to have a significant impact on the company's current financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH's Subsidiary Receives Approval for Supplemental Applications of Cefuroxime Sodium and Candesartan Cilexetil Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH's Subsidiary Receives Approval for Supplemental Applications of Cefuroxime Sodium and Candesartan Cilexetil Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-11 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the \"Drug Supplemental Application Approval Notice\" from the National Medical Products Administration for Cefuroxime Sodium for Injection 0.5g (calculated as C16H16N4O8S) and Candesartan Cilexetil Tablets 4mg. The approval indicates that the impurity pharmaceutical research for these drugs has been recognized, which is expected to enhance the quality control capabilities and market competitiveness of these products. This approval is not expected to have a significant impact on the company's current financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1152675607","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152675607","pubTimestamp":1778492308,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the \"Drug Supplemental Application Approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK1515":"抗疫概念","BK0070":"员工持股","BK1574":"生物医药B类股","BK1606":"中医药概念","BK0196":"行业龙头","00874":"白云山","BK0097":"医药电商","BK1197":"保健护理产品经销商","BK0239":"医药制造","BK1521":"挪威政府全球养老基金持仓","BK0096":"民营医院","01477":"欧康维视生物-B","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","BK1191":"制药","BK0175":"白马股"},"translate_title":"白云山PH子公司头孢呋辛钠坎地沙坦酯片补充申请获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"01477":1,"00874":1},"content_text":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Tianxin Pharmaceutical), has recently received the \"Drug Supplemental Application Approval Notice\" from the National Medical Products Administration for Cefuroxime Sodium for Injection 0.5g (calculated as C16H16N4O8S) and Candesartan Cilexetil Tablets 4mg. The approval indicates that the impurity pharmaceutical research for these drugs has been recognized, which is expected to enhance the quality control capabilities and market competitiveness of these products. This approval is not expected to have a significant impact on the company's current financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}